PHGN Stock Chart & Stats
CHF0.82
CHF0.00(0.00%)
―
--
Day’s Range― - ―
52-Week RangeCHF0.82 - CHF0.96
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
CHF667.29M
Enterprise ValueCHF934.02
Total Cash (Recent Filing)CHF158.25M
Total Debt (Recent Filing)CHF126.73M
Price to Earnings (P/E)80.1
Beta2.25
Next Earnings
Nov 05, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding707,781,250
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-2.78
Price to Book (P/B)3.72
Price to Sales (P/S)2.74
P/FCF Ratio20.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)CHF366.87M
Bulls Say, Bears Say
Bulls Say
Joenja Growth And ExpansionStrong Joenja growth, rising patient identification and geographic rollout support a durable expansion path. Pediatric label work could broaden the addressable APDS population, while international launches diversify growth beyond the U.S. market.
High Gross Margins And Cost DisciplineThe specialty-drug model produces substantial gross profit, giving Pharming resources to fund development. Structural G&A reductions and tighter expense control can help preserve operating leverage while management reallocates investment toward higher-potential pipeline programs.
Improved Profitability And LeverageThe return to positive earnings and operating cash flow marks a meaningful improvement from 2023–2024 losses. Lower relative leverage and increased equity provide greater financial flexibility to support commercialization and pipeline investment.
Bears Say
Revenue Slowdown And RUCONEST CompetitionThe guidance reduction indicates that near-term growth is weakening, while a new oral HAE competitor and international withdrawal pressure RUCONEST. Continued erosion in the established product could offset Joenja growth and constrain consolidated revenue momentum.
Volatile Cash Generation And Manufacturing ChargesRecent cash outflows and working-capital needs show that reported profitability does not always translate into steady cash generation. Inventory impairment and manufacturing restructuring also signal execution risk that could reduce funds available for commercial and clinical programs.
Pipeline Approval UncertaintyPotential expansion of Joenja into CVID and broader PID markets could be significant, but it depends on additional trials and regulatory approval. Delays, inconclusive data or extra development costs would postpone revenue and limit the pipeline's diversification benefits.
Pharming Group News
PHGN FAQ
What was Pharming Group’s price range in the past 12 months?
Pharming Group lowest stock price was CHF0.82 and its highest was CHF0.96 in the past 12 months.
What is Pharming Group’s market cap?
Pharming Group’s market cap is CHF667.29M.
When is Pharming Group’s upcoming earnings report date?
Pharming Group’s upcoming earnings report date is Nov 05, 2026 which is in 69 days.
How were Pharming Group’s earnings last quarter?
Pharming Group released its earnings results on Jul 30, 2026. The company reported CHF0.002 earnings per share for the quarter, missing the consensus estimate of CHF0.005 by -CHF0.003.
Is Pharming Group overvalued?
According to Wall Street analysts Pharming Group’s price is currently same.
Does Pharming Group pay dividends?
Pharming Group does not currently pay dividends.
What is Pharming Group’s EPS estimate?
Pharming Group’s EPS estimate is <0.01.
How many shares outstanding does Pharming Group have?
Pharming Group has 707,781,250 shares outstanding.
What happened to Pharming Group’s price movement after its last earnings report?
Pharming Group reported an EPS of CHF0.002 in its last earnings report, missing expectations of CHF0.005. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Pharming Group?
Currently, no hedge funds are holding shares in CH:PHGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharming Group
Based in Leiden, the Netherlands, Pharming Group N.V. operates as a biopharmaceutical firm dedicated to advancing and marketing protein replacement therapies and precise medical solutions. Its global efforts, spanning the United States, Europe, and other international markets, focus on addressing rare diseases and critical unmet medical needs. The company's flagship product, Ruconest, is a recombinant human C1 esterase inhibitor prescribed for managing acute attacks of hereditary angioedema. Pharming's development pipeline also encompasses rhC1INH, which is under investigation for potential applications in pre-eclampsia, acute kidney injury, and COVID-19. Furthermore, they are progressing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor, for individuals afflicted with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy aimed at treating Pompe and Fabry diseases. The company maintains significant partnerships, including a development and license agreement with Novartis and a strategic alliance with Orchard Therapeutics plc. This latter collaboration involves the research, development, manufacture, and commercialization of OTL-105, an experimental ex-vivo autologous hematopoietic stem cell gene therapy designed to treat hereditary angioedema.
PHGN Company Deck
PHGN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of meaningful commercial and clinical positives—most notably strong Joenja growth, resilient RUCONEST patient metrics, and near‑term clinical catalysts—against tangible near‑term headwinds including a $30M revenue guidance reduction, RUCONEST year‑over‑year sales decline, manufacturing inventory impairments, and operating cash outflows. Management emphasized cost discipline, maintained positive operating profitability in the quarter, and outlined multiple growth levers (pediatric and geographic expansion for Joenja, two Phase II readouts in Q4, and a 2027 pivotal readout for napazimone). Given the balance of clear growth drivers and pipeline upside against notable short‑term financial and operational challenges, the tone is constructive but cautious.View all CH:PHGN earnings summaries